IDEXX Laboratories, Inc. (NASDAQ:IDXX) SVP Sells $4,704,586.26 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Free Report) SVP George Fennell sold 8,198 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

IDEXX Laboratories Trading Down 0.2 %

Shares of NASDAQ:IDXX opened at $572.21 on Monday. The company has a market capitalization of $47.52 billion, a P/E ratio of 56.82, a P/E/G ratio of 3.16 and a beta of 1.25. IDEXX Laboratories, Inc. has a 1 year low of $372.50 and a 1 year high of $579.68. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.02. The business’s 50 day simple moving average is $540.92 and its 200 day simple moving average is $490.92.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.13 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEXX Laboratories

Large investors have recently modified their holdings of the business. Intech Investment Management LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $893,000. Westfield Capital Management Co. LP lifted its stake in shares of IDEXX Laboratories by 10.6% in the 4th quarter. Westfield Capital Management Co. LP now owns 161,104 shares of the company’s stock valued at $89,421,000 after acquiring an additional 15,492 shares during the last quarter. Skopos Labs Inc. bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $238,000. Eagle Global Advisors LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $266,000. Finally, HCR Wealth Advisors bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $201,000. Institutional investors and hedge funds own 86.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IDXX. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler lowered IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a report on Tuesday, January 30th. Barclays upped their target price on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $500.00 to $460.00 and set a “hold” rating on the stock in a report on Monday, October 30th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Friday, January 5th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $591.50.

View Our Latest Analysis on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Get Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.